

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

of

7

**Complete if Known**

Application Number

09/514,113
------------

Filing Date

February 25, 2000

First Named Inventor

Frank B. Dean	
---------------	--

### Group Art Unit

~~1646~~ 1655

Examiner Name

315504 B.L

Attorney Docket Number

MSI 100

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examine  
Signature**

B. Z. Lissner

Date Considered

10/18/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/514,113
		Filing Date	February 25, 2000
		First Named Inventor	Frank B. Dean
		Group Art Unit	1655
		Examiner Name	51550N
Sheet 1 of 7	Attorney Docket Number	MSI 100	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B.F.		ASSELINE, et al., "Solid-phase preparation on 5', 3'-Heterobifunctional oligonucleotides using modified solid supports," <i>Tetrahedron</i> 48:1233-1254 (1992).	
		BANER, et al., "Signal amplification of padlock probes by rolling circle replication," <i>Nucleic Acids Res.</i> 26(22):5073-8 (1998).	
		BEIGELMAN, et al., "Synthesis of 1-Deoxy-D-Ribofuranase phosphoramidite and the incorporation of abasic nucleotides in stem-loop II of a hammerhead ribozyme," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 4(14):1715-1720 (1994)	
		BIRKENMEYER & MUSHAHWAR, "DNA probe amplification methods," <i>J. Virological Methods</i> 35:117-126 (1991)	
		BLOCH, et al., "Alpha-anomeric DNA: beta-RNA hybrids as new synthetic inhibitors of <i>Escherichia coli</i> RNase H, <i>Drosophila</i> embryo RNase H and M-MLV reverse transcriptase," <i>Gene</i> 72(1-2):349-60 (1988).	
		BROWNIE, et al., "The elimination of primer-dimer accumulation in PCR," <i>Nucleic Acids Res.</i> 25(16):3235-41 (1997).	
		COCUZZA, "A phosphoramidite reagent for automated solid phase synthesis of 5'-biotinylated oligonucleotides," <i>Tetrahedron Lett.</i> 30:6287-6290 (1989).	
		COMPTON, "Nucleic acid sequence-based amplification," <i>Nature</i> . 350(6313):91-2 (1991).	
		CONNOLLY & RIDER, "Chemical synthesis of oligonucleotides containing a free sulphhydryl group and subsequent attachment of thiol specific probes," <i>Nucleic Acids Res.</i> 13(12):4485-502 (1985).	
B.F.		CONNOLLY, "The synthesis of oligonucleotides containing a primary amino group at the 5'-terminus," <i>Nucleic Acids Res.</i> 15(7):3131-9 (1987).	

Examiner's Signature	B.F. Simon	Date Considered	10/19/00
----------------------	------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 		Application Number	09/514,113
		Filing Date	February 25, 2000
		First Named Inventor	Frank B. Dean
		Group Art Unit	16.55
		Examiner Name	SISSON, B.
Sheet 3 of 7	Attorney Docket Number	MSI 100	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
818		CRAXTON, et al., "Linear amplification sequencing, a powerful method for sequencing DNA," <i>Methods: A Companion in Methods in Enzymology</i> 3:20-26 (1991).	
		DOLINNAYA, et al., "Oligonucleotide circularization by template-directed chemical ligation," <i>Nucleic Acids Res.</i> 21(23):5403-7 (1993).	
		DREYER & DERVAN, "Sequence-specific cleavage of single-stranded DNA: oligodeoxynucleotide-EDTA X Fe(II)," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 82(4):968-72 (1985).	
		DURAND, et al., "Circular dichroism studies of an oligodeoxyribonucleotide containing a hairpin loop made of a hexaethylene glycol chain: conformation and stability," <i>Nucleic Acids Res.</i> 18(21):6353-9 (1990).	
		EGHOLM, et al., "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," <i>J. Am. Chem. Soc.</i> 114:1895-1897 (1992).	
		FERRIE, et al., "Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene," <i>Am. J. Hum. Genet.</i> 51(2):251-62 (1992).	
		GRZYBOWSKI, et al., "Synthesis and antibody-mediated detection of oligonucleotides containing multiple 2,4-dinitrophenyl reporter groups," <i>Nucleic Acids Res.</i> 21(8):1705-12 (1993).	
		GUPTA, et al., "A universal solid support for the synthesis of 3'-thiol group containing oligonucleotides," <i>Tetrahedron Lett.</i> 31:2471-2474 (1990).	
		HURYN & OKABE, "AIDS-driven nucleoside chemistry," <i>Chem. Rev.</i> 92:1745-1768 (1992).	
818		JABLONSKI, et al., "Preparation of oligodeoxynucleotide-alkaline phosphatase conjugates and their use as hybridization probes," <i>Nucleic Acids Res.</i> 14(15):6115-28 (1986).	

Examiner's Signature	B. L. Lison	Date Considered	10/19/00
----------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



## Complete if Known

Application Number	09/514,113
Filing Date	February 25, 2000
First Named Inventor	Frank B. Dean
Group Art Unit	1655
Examiner Name	S. L. S. W. B. C.
Attorney Docket Number	MSI 100

Sheet 1 of 7

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B. F.		JONES, et al., "Studies on the alkylation of 2', 3'-O-isopropylideneuridine," <i>J. Carbohydrates, Nucleosides, Nucleotides</i> 4:301-6 (1977).	
		JUN-DONG & LI-HE, "Application of Wittig reaction to adenosine derivatives," <i>Synthesis</i> 909-911 (1990).	
		KALNIK, et al., "NMR studies of abasic sites in DNA duplexes: Deoxyadenosine stacks into the helix opposite the cyclic analogue of 2-Deoxyribose," <i>Biochemistry</i> 27:924-931 (1998)	
		KUMAR, et al., "A simple method for introducing a thiol group at the 5'-end of synthetic oligonucleotides," <i>Nucleic Acids Res.</i> 19(16):4561 (1991).	
		LANDEGREN, "Molecular mechanics of nucleic acid sequence amplification," <i>Trends Genet.</i> 9(6):199-204 (1993).	
		LANDEGREN, et al., "A ligase-mediated gene detection technique," <i>Science</i> 241:1077-1080 (1988).	
		LI, et al., "Enzyme-linked synthetic oligonucleotide probes: non-radioactive detection of enterotoxigenic Escherichia coli in faecal specimens," <i>Nucleic Acids Res.</i> 15(13):5275-87 (1987).	
		LIZARDI, et al., "Mutation detection and single-molecule counting using isothermal rolling-circle amplification," <i>Nat. Genet.</i> 19(3):225-32 (1998).	
		MACKELLAR, et al., "Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups," <i>Nucleic Acids Res.</i> 20(13):3411-7 (1992).	
B. F.		MATRAY & KOOL, "A specific partner for abasic damage in DNA," <i>Nature</i> 399(6737):704-8 (1999).	

Examiner's Signature	B. F. L. L. L.	Date Considered	10/19/00
----------------------	----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  JUN 30 2000 PATENT & TRADEMARK OFFICE		Application Number	09/514,113
		Filing Date	February 25, 2000
		First Named Inventor	Frank B. Dean
		Group Art Unit	1655
		Examiner Name	Sisson, B.L.
Sheet 5 of 7	Attorney Docket Number	MSI 100	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B.F.		MORAN, et al., "Non-hydrogen bonding 'terminator' nucleosides increase the 3'-end homogeneity of enzymatic RNA and DNA synthesis," <i>Nucleic Acids Res.</i> 24(11):2044-52 (1996).	
		NELSON, "Rapid detection of genetic mutations using the chemiluminescent hybridization protection assay (HPA): overview and comparison with other methods," <i>Crit. Rev. Clin. Lab. Sci.</i> 35(5):369-414 (1998).	
		NELSON, et al., "Oligonucleotide labeling methods. 3. Direct labeling of oligonucleotides employing a novel, non-nucleosidic, 2-aminobutyl-1,3-propanediol backbone," <i>Nucleic Acids Res.</i> 20(23):6253-9 (1992).	
		NIELSEN, et al., "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide," <i>Science</i> 254(5037):1497-500 (1991).	
		PIELES & ENGLISH, "Psoralen covalently linked to oligodeoxyribonucleotides: synthesis, sequence specific recognition of DNA and photo-cross-linking to pyrimidine residues of DNA," <i>Nucleic Acids Res.</i> 17(1):285-99 (1989).	
		PIELES, et al., "Preparation of a novel psoralen containing deoxyadenosine building block for the facile solid phase synthesis of psoralen-modified oligonucleotides for a sequence specific crosslink to a given target sequence," <i>Nucleic Acids Res.</i> 17:8967-78 (1989).	
		RAY & JAXA-CHAMIEC, "Novel thymidine analogues via reaction of unprotected 5'-Deoxy-5'-iodothymidine with dianions," <i>Heterocycles</i> 31(10):1777-1780 (1990).	
		ROBINS & WOUK, "Fluorination at C5' of nucleosides, synthesis of the new class of 5'-Fluoro-5'-S-Aryl (Alkyl) thionucleosides from adenosine," <i>Tetrahedron Lett.</i> 29:5729-32 (1988).	
		SALUNKHE, et al., "Control of folding and binding of oligonucleotides by use of a nonnucleotide linker," <i>J. Amer. Chem. Soc.</i> 114:8768-8772 (1992).	
B.F.		SÉQUIN, "Nucleosides and nucleotides. Part 7. Four dithymidine monophosphates with different anomeric configurations, their synthesis and behaviour towards phosphodiesterases," <i>Helv. Chim. Acta.</i> 57(1):68-81 (1974).	

Examiner's Signature	B. L. Sisson	Date Considered	10-19-00
----------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/514,113
		Filing Date	February 25, 2000
		First Named Inventor	Frank B. Dean
		Group Art Unit	1655
		Examiner Name	Sisson, B.L.
Sheet 1 of 7		Attorney Docket Number	MSI 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
3/8		SINHA & COOK, "The preparation and application of functionalised synthetic oligonucleotides: III. Use of H-phosphonate derivatives of protected amino-hexanol and mercapto-propanol or -hexanol," <i>Nucleic Acids Res.</i> 16(6):2659-69 (1988).	
		SPROAT, et al., "The synthesis of protected 5'-mercapto-2',5'-dideoxyribonucleoside-3'-O-phosphoramidites; uses of 5'-mercapto-oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 15(12):4837-48 (1987).	
		STEIN, et al., "Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro," <i>Biochemistry</i> 30(9):2439-44 (1991).	
		STUMP, et al., "The use of modified primers to eliminate cycle sequencing artifacts," <i>Nucleic Acids Res.</i> 27(23):4642-8 (1999).	
		TAKASUGI, et al., "Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 88(13):5602-6 (1991).	
		TAKESHITA, et al., "Oligodeoxynucleotides containing synthetic abasic sites. Model substrates for DNA polymerases and apurinic/apyrimidinic endonucleases," <i>J. Biol. Chem.</i> 262(21):10171-9 (1987).	
		TANAKA, et al., "Cleavage of a nucleosidic oxetane with carbanions: synthesis of a highly promising candidate for anti-HIV agents: A phosphokate isosters O AZI' 5'-phosphate," <i>Tetrahedron Lett.</i> 30:2567-2570 (1989)	
		THOMAS, et al., "Amplification of padlock probes for DNA diagnostics by cascade rolling circle amplification or the polymerase chain reaction," <i>Arch. Pathol. Lab. Med.</i> 123(12):1170-6 (1999).	
		THOUNG & CHASSIGNOL, "Solid phase synthesis of oligo- and oligo- -deoxynucleotides," <i>Tetrahedron Lett.</i> 29:5905-8 (1988).	
3/8		WALKER, et al., "Strand displacement amplification--an isothermal, in vitro DNA amplification technique," <i>Nucleic Acids Res.</i> 20(7):1691-6 (1992).	

Examiner's Signature	B. L. Sisson	Date Considered	10/19/00
----------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/514,113	
		Filing Date	February 25, 2000	
		First Named Inventor	Frank B. Dean	
		Group Art Unit	1655	
		Examiner Name	51550N, B.2.	
Sheet	of	7	Attorney Docket Number	MSI 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B.F.		WALKER, et al., "Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 89(1):392-6 (1992).	
		WILL, et al., "The synthesis of oligonucleotides that contain 2,4-dinitrophenyl reporter groups," <i>Carbohydr. Res.</i> 216:315-22 (1991).	
		ZHANG, et al., "Amplification of target-specific, ligation-dependent circular probe," <i>Gene</i> 211(2):277-85 (1998).	
B.F.		ZUCKERMANN, et al., "Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides," <i>Nucleic Acids Res.</i> 15(13):5305-21 (1987).	

Examiner's Signature	B. F. Lison	Date Considered	10/19/00
----------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.